Rebinyn, a recombinant DNA-derived coagulation Factor IX concentrate, temporarily replaces the missing coagulation Factor IX in hemophilia B patients. Novo Nordisk announced that the Food and Drug ...
MISSISSAUGA, ON, April 11, 2018 /CNW/ - Today, in Canada, Novo Nordisk announced the launch and availability of Rebinyn ® (Coagulation Factor IX (Recombinant), pegylated), an anti-hemophilic factor ...
Rebinyn is a recombinant DNA-derived coagulation Factor IX concentrate with an extended half-life. The Food and Drug Administration (FDA) has expanded the approval of Rebinyn ® (coagulation factor IX ...
PLAINSBORO, N.J., May 21, 2018 /PRNewswire/ -- A new head-to-head pharmacokinetic study showed that adults with hemophilia B who received a single dose (50 IU/kg) of Rebinyn ® [Coagulation Factor IX ...
Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for Rebinyn for the treatment of adults and children with haemophilia B. Rebinyn is ...
Here are three things to know. Rebinyn is intended to treat adults and children with hemophilia B, an inherited blood disorder that causes prolonged or spontaneous bleeding. Patients may take the drug ...
Bagsværd, Denmark, 31 May 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for REBINYN ® for the treatment of adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback